Does a Polycistronic 2A Design Enable Functional FcRn Production for Antibody Pharmacokinetic Studies?
<b>Background/Objectives:</b> The neonatal Fc receptor (FcRn) is a heterodimeric protein composed of a heavy α-chain with an MHC class I-like fold and β<sub>2</sub>-microglobulin. It plays a crucial role in maintaining the homeostasis and pharmacokinetics of immunoglobulin G (IgG) and albumin through pH-dependent recycling. The production of soluble recombinant FcRn is technically challenging due to its heterodimeric structure and the presence of a transmembrane domain. This study aimed to develop a polycistronic construct enabling the co-expression of FcRn subunits from a single transcript and to evaluate the functional activity of the resulting protein in CHO-K1 cells. <b>Methods:</b> Integration vectors (pComV-FcRn-B2M) were designed to encode FcRn and β<sub>2</sub>-microglobulin linked via self-cleaving 2A peptides (P2A, E2A, F2A, T2A). Stable producer cell lines were generated using the Sleeping Beauty transposon system. The purified proteins were characterized by SDS-PAGE, Western blotting, and size-exclusion chromatography (SEC). Functional activity was assessed by ELISA and bio-layer interferometry (BLI). <b>Results:</b> Electrophoretic and chromatographic analyses confirmed the expected subunit composition and demonstrated that over 95% of the recombinant protein was monomeric. Functional assays revealed pH-dependent IgG binding, with strong interaction at pH 6.0 and negligible binding at pH 7.5. BLI measurements showed high affinity consistent with native FcRn function (KD = 3.15 nM at pH 6.0). <b>Conclusions:</b> The developed polycistronic construct containing a P2A peptide with a GSG linker enabled efficient production of functional FcRn in CHO-K1 cells (yield up to 2.23 mg/mL). The P2A variant demonstrated the highest efficiency and can serve as a reference system for screening Fc-engineered antibodies with optimized pharmacokinetic properties.
Authors
- Valentina S. Nesmeyanova (ORCID: https://orcid.org/0000-0003-1091-3586)
- Elena A. Rukhlova (ORCID: https://orcid.org/0000-0002-3465-4577)
- S. E. Olkin (ORCID: https://orcid.org/0009-0006-7158-9889)
- Maksim N. Kosenko (ORCID: https://orcid.org/0000-0002-8023-0601)
- Nikita D. Ushkalenko (ORCID: https://orcid.org/0000-0002-2171-7444)
- Д. Н. Щербаков (ORCID: https://orcid.org/0000-0001-8023-4453)
- Ivan M. Susloparov (ORCID: https://orcid.org/0000-0002-9718-7339)
Institutions
- State Research Center of Virology and Biotechnology VECTOR (RU)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3390/pharmaceutics17111463
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00